<p>OpGen (NASDAQ: OPGN) news for Monday includes OPGN stocks starting after an update of coronavirus testing packages from China.
A press release from OpGen reveals that Curetis now offers paid test packages for the new coronavirus. The test packages come from Cureti’s strategic partner BGI, which is based in Shenzhen, China.
These kits already received approval from Chinese authorities earlier this year. They also received CE-IVD certification on 28 February 2020 to comply with European rules. The kits allow doctors to test for coronavirus via nasopharyngeal swabs and bronchoalveolar lavage fluid.
In OpGEN’s press release, it is noted that Curetis will offer these coronavirus test packages to doctors in Europe via the company’s distribution network. The kits also come directly from the company in countries where it does not have a distribution network.
Evan Jones, Chairman of the Board and CEO of OpGen, said this about the OPGN share.
“We commend both Curetis and BGI Group for quickly bringing this important product to market at a time of greatest need. As Covid-19 spreads around the world, rapid testing techniques will be crucial for the containment and ultimate treatment of the outbreak in Europe and beyond. “
OpGen and Curetis are currently working on a merger that started on September 4, 2019. The deal has not yet been completed and the two continue to act as separate companies right now.
The OPGN share increased by 128.11% as of Monday afternoon.
At the time of writing, William White had no position in any of the above securities.